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Introduction 
 
Aerobic deconditioning occurs during long duration space flight despite the use of 
exercise countermeasures (Convertino, 1996).  As a part of International Space Station 
(ISS) medical operations, periodic tests designed to estimate aerobic capacity are 
performed to track changes in aerobic fitness and to determine the effectiveness of 
exercise countermeasures. These tests are performed prior to, during, and after missions 
of greater than 30 days in duration. 
 
Crewmembers selected for missions aboard the ISS perform a graded exercise test on a 
cycle ergometer approximately 270 days prior to their scheduled launch date in order to 
measure peak oxygen consumption (VO2PK) and peak heart rate (HRpk).  Approximately 
30 to 45 days prior to launch, crewmembers perform a submaximal cycle ergometer test 
at work rates set to elicit 25, 50 and 75% of their pre-flight VO2PK. This test, known as 
the Periodic Fitness Evaluation (PFE), serves as a baseline measure to which subsequent 
in-and post-flight exercise tests are compared.  While onboard the ISS, crewmembers are 
normally scheduled to perform the PFE beginning with flight day (FD) 14 and every 30 
days thereafter.  The PFE is also conducted 5 and 30 days following flight. 
 
Using PFE data, aerobic fitness is estimated by quantifying the VO2 vs. HR relationship 
using linear regression and calculating the VO2 that would occur at the crewmember’s 
previously measured HRpk.  Currently, for data collected during flight, this technique 
assumes that the pre- vs. in-flight oxygen consumption per given cycle workload is 
similar.  However, the validity of this assumption is based upon a sparse amount of data 
collected during the Skylab era (Michel, et al. 1977).  The method of using heart rate and 
cycle ergometer work rates has been used to estimate aerobic fitness in normal gravity 
(Astrand and Ryhming, 1954; Lee, 1993).  Due to spaceflight induced physiological 
alterations, such as shifts in extracellular fluid (e.g. plasma) volume, this method may not 
be valid during space flight.  In addition, the ergometer onboard ISS is vibration-isolated 
and moves with the astronaut’s application of force into the pedals.  The effect of this 
movement on the VO2 of cycle exercise on ISS has not been quantified. 
 
Though the measurement of VO2 during ISS flight has not been conducted to date, it has 
been a long-waived requirement found within the International Space Station Medical 
Operations Requirement Document (ISS MORD), Rev C.  An attempt to meet this 
requirement was made using accessories for the Gas Analyzer System for Metabolic 
Analysis Physiology (GASMAP).  The GASMAP is a mass spectrometer and was 
developed by the NASA’s ISS Human Research Facility (HRF) to support multiple 
studies on-board ISS, including measurements of VO2 during exercise.  However, 
ground-based laboratory testing showed that, though the GASMAP mass spectrometer 
performed well in the analysis of static gas samples, the software used to measure VO2 
was not accurate (A. Moore, personal communication, February 2000).  Subroutines 
within the software were unable to calibrate the turbine flowmeter using a standard three 
liter calibration syringe.  Further, the delay calculation required to measure breath by 
breath VO2 was continuously out of phase and unable to align the expired gas fractions 
with the corresponding expired ventilation measurement.  When compared to the Johnson 
Space Center Exercise Physiology Lab’s (EXL) reference metabolic gas analysis system, 
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the GASMAP was 24 and 11% higher for submaximal workloads of 25 and 50% VO2 
peak, respectively.  It was concluded that without further design and software 
modifications, the GASMAP was not an adequate device for measuring VO2 on ISS.  The 
expense of engineering support and hardware modifications required to configure the 
GASMAP to perform accurate measures of VO2 was considered prohibitive at the time 
and were not implemented. 
 
A device capable of measuring exercise VO2 on-board ISS has recently been developed 
by a contractor to the European Space Agency.  The device, known as the Pulmonary 
Function Module/Photoacoustic Analyzer Module (PFM/PAM) is part of the ISS 
Pulmonary Function System (PFS).  For the purposes of this report, the PFS/PAM and 
PFS will be referred to simply as the PFS.  The PFS is located in the Human Research 
Facility (HRF) Rack 2 of the Destiny Laboratory on-board the ISS. The manufacturer of 
the PFS, Damec, (Damec Research ApS, Odense, Denmark) has a history of developing 
equipment designed to measure the effects of microgravity on the human respiratory 
system.  Previous products by this company include the Respiratory Monitoring System 
(RMS) for the Anthrorack used during the Space Lab missions, the RMS-II used during 
the EuroMir 95 mission, and the Advanced Respiratory Monitoring System used aboard 
STS-107.  
 
The PFS system was initially launched to the ISS aboard STS-114 (LF 1) in July 2005, 
followed by a hardware upgrade, which was launched on a Russian Progress supply 
vehicle on April 2006.  A collaborative effort has been initiated between NASA and ESA 
Life Sciences personnel to integrate the use of the PFS into the PFE tests for the support 
of Medical Operations objectives.  Jensen et al. (2002) performed an in depth comparison 
of the AMIS 2001, the commercial version of the PFS, versus the standard Douglas bag 
method and found that the system was reliable and accurate for measuring VO2.  
However, prudence dictates that an evaluation of the flight-like PFS device is required to 
determine if it provides valid metabolic gas analysis prior to implementation on-board 
ISS. 
 
Purpose 
The purpose of this investigation was to compare exercise metabolic gas analysis 
measurements (including VO2) obtained by the PFS to those collected using a reference 
metabolic gas analysis system (the ParvoMedics TrueOne© 2400 system).  The 
ParvoMedics TrueOne© 2400 system has been extensively validated (Basset, et al, 2001; 
Crouter, et al, 2006) and is currently utilized by the NASA’s Exercise Physiology 
Laboratory for pre- and post-flight testing astronauts assigned to ISS flights. 
Methods 
Subjects 
Eight healthy male subjects volunteered to perform two peak cycle tests over a period of 
12 days (Table 1).  All subjects completed a modified Air-Force Class III physical exam 
prior to participation and received written and verbal explanations of test protocols before 
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providing written informed consent. Test protocols and procedures were reviewed and 
approved by the NASA-Johnson Space Center Committee for the Protection of Human 
Subjects. 
 
 
Table 1. Subject Characteristics (mean ± SD) 
 
Characteristic n = 8
Age (yrs) 33 ± 6 
Height (cm) 181.9 ± 5.0 
Weight (kg) 82.2 ± 9.1 
VO2 PK (l·min-1) 4.55 ± 0.82 
VO2 PK (ml·kg-1·min-1) 55.9 ± 14.9 
 
Protocol 
Each subject performed two peak cycle ergometer tests.  The ergometer used for testing 
was a LODE Excalibur Sport (LODE, AN Groningen, The Netherlands).  Metabolic gas 
analysis was accomplished using one of two systems in random order: the ParvoMedics 
TrueOne© 2400 (ParvoMedics, Salt Lake City, UT) metabolic gas analysis system or the 
PFS.  Subjects completed the two tests within a 12 day period.  A minimum of 48 hours 
was allowed between each test to prevent residual soreness and fatigue.  Sessions were 
conducted at approximately the same time of day, limiting variance to within ± 2 hours of 
the initial testing session to limit any circadian effect on physiological variance (Carter, 
2002). Subjects were also requested to maintain the same dietary and sleeping habits 
throughout the testing period.  Compliance was monitored through a subject screening 
form that was completed by the subject before each test.  
 
Metabolic gas analysis was conducted continuously throughout the cycle test protocol 
(Figure 1).  The cycle work rate was increased according to the protocol until the subject 
indicated that they could no longer continue.  Each subject was allowed to choose their 
desired pedal cadence (revolutions per minute; RPM) and was required to maintain that 
same cadence throughout the two tests. Lepers, et al. (2001) found no difference in VO2 
when subjects were allowed to choose their optimal cadence between 70 and 100 RPMs. 
All test subjects in the current evaluation maintained a pedal cadence within a range of 
80-100 RPMs. 
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Figure 1. Peak Cycle Protocol 
 
Heart rate was measured electrocardiographically (Q-Stress, Quinton Instruments, 
Seattle, WA) and blood pressure was measured using a mercurial sphygmomanometer 
and stethoscope.  Ratings of Perceived Exertion (RPE) were reported during the last 30 
seconds of each stage. Blood pressure was not recorded above 250 watts (W) if the 
subject showed a normal blood pressure response to increases in workload for workloads 
below 250 W. Immediately post exercise, blood pressure was recorded and the subject 
was monitored for any adverse effects caused by maximal exertion. 
Metabolic Gas Analysis Systems Description 
 
The ParvoMedics TrueOne© 2400 metabolic gas analysis system uses a paramagnetic 
oxygen analyzer (operating range 0-25% O2) and an infrared single beam, single wave 
length carbon dioxide analyzer (operating range 0-15% CO2) to measure the composition 
of expired gasses.  The subject inspires through a two-way non-rebreathing valve (Hans 
Rudolph Model 2700, Kansas City, MO, USA) and expired air composition is analyzed 
in a 4 liter mixing chamber.  The inspired gas composition is assumed to be standard 
atmospheric values (i.e. 20.93% O2 and 0.03% CO2).  Expired ventilation is measured 
using a Hans Rudolph Model 3813 linear pneumotach (operating flow range 0-800 
L/min).  Computational software is provided with the system and runs with the Windows 
XP Professional operating system. 
 
The Damec Pulmonary Function System uses two types of technology for gas analysis.  
For carbon dioxide, a photo-acoustic method of gas analysis is utilized.  In this technique, 
the gas sample is exposed to intermittent infrared light.  The gas sample absorbs the light 
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and the absorbed energy results in a rise in pressure by heating.  The intermittent infrared 
light is divided into different pulsation frequencies and is filtered optically.  Each optical 
filter allows only a specific wavelength of light to pass through and the wavelengths 
correspond to the infrared absorption spectra of the sample gasses.  When the light-source 
is removed, the gas cools down, resulting in a pressure fluctuation.  By choosing a 
pulsation frequency in the audible range, the pressure fluctuation becomes an acoustic 
signal which is detected by a microphone.  The audible sounds recorded by the 
microphone are analyzed and the amplitude of each signal is used to calculate the gas 
concentration.  The operating range for carbon dioxide is from 0-12%.  Gasses other than 
carbon dioxide can be detected utilizing the photo-acoustic method, but an evaluation of 
these was beyond the scope of our investigation.  For oxygen analysis, an Oxigraf™ 
sensor is used in the PFS.  The Oxigraf™ technology is based on a laser diode absorption 
spectroscopy technique.  The sample gas is exposed to a laser tuned to a wavelength of 
760 nm (the peak of oxygen absorption).  The laser signal is attenuated in proportion to 
the concentration of oxygen present in the sample.  The operating range is from 0-100%. 
 
When the PFS is used during exercise testing, the subject inspires through a custom-
designed (Damec Research Aps., Odense, Denmark) two-way non-rebreathing valve and 
the expired gasses are sampled in a 15 liter anesthesia bag, which serves as a mixing 
reservoir.  Inspired gas concentrations are measured on the inspired side of the respiratory 
circuit.  This is done because inspired gas concentrations on board the spacecraft 
typically deviate slightly from normal atmospheric values.  Ventilation is measured on 
the inspired side of the non-rebreathing valve using a Damec custom-designed 
pneumotach (operating flow range 0-900 L/min). 
 
Metabolic Gas Analysis Data Reduction 
Data were collected continuously by the ParvoMedics and PFS systems.  Data were 
averaged in 30-second intervals to the nearest whole breath.  Peak VO2 was accepted as 
the highest VO2 attained for a single 30-second period.  The dependent variables in this 
investigation were VO2, carbon dioxide production (VCO2), pulmonary ventilation (VE), 
and fractions of expired oxygen and carbon dioxide (FEO2 and FECO2).  Custom data 
reduction templates were created using Microsoft Excel (Microsoft Corporation, 
Redmond, WA). 
 
Data collected using the ParvoMedics were automatically reduced to 30-second intervals 
by the ParvoMedics software. The exported data were further reduced using a data 
reduction template and averaged over the last 30-seconds of each stage.  The 
ParvoMedics sampled the QRS signal directly from the Q-Stress ECG system and 
calculated heart rate. Heart rate data were reduced in the same fashion as the metabolic 
gas analysis variables. 
 
Damec provided a Ground Support Equipment (GSE) software package to calculate the 
dependent measures from the raw data signals measured by the PFS.  Similar to the 
ParvoMedics data, all PFS data were reduced in 30-second intervals and exported to 
Excel.  A data cable to collect heart rate data from the Q-Stress ECG system directly by 
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the PFS was not available; therefore HR data were entered into the PFS data reduction 
template from the Q-Stress ECG printout. 
Data Analysis 
Data analysis for each dependent variable was conducted as a series of pre-planned 
comparisons (dependent T-tests with a Bonferroni adjustment made for multiple 
comparisons).  This data reduction strategy was selected instead of the more traditional 
analysis of variance for two reasons.  The first is that the dependent measurements (VO2, 
VCO2, and VE) will increase with exercise intensity – there was no need for a statistical 
test to corroborate a physiological certainty.  The second is that the primary question of 
interest involves determining if the measured metabolic gas analysis variables differed 
between the devices at any stage of exercise.  Testing of this question is much more 
straightforward using preplanned comparisons.  A significant difference was deemed to 
occur if p<0.05.  A linear regression analysis comparing the VO2 data collected from both 
devices across all exercise stages was also performed and confidence intervals developed 
for the slope and intercept of the relationship.  Finally, a comparison of the peak VO2 
data attained from each of the devices was performed using a paired T-test. 
 
Results 
 
The average work rate attained by the subjects was 319 ± 53 W.  All subjects completed 
each exercise stage through 250 W.  Therefore, the planned comparisons of the 
dependent variables were conducted at 100, 150, 200 and 250 W. 
Oxygen Consumption (VO2) 
Oxygen consumption did not differ between devices at 100, 200, and 250 W; however, a 
statistically significant difference between the devices was observed at the 150 W stage 
(Figure 2).  The percent difference in VO2 between the two devices was 5.4% at this 
stage.  When the VO2 values measured on the ParvoMedics and the PFS were compared 
using linear regression, the Pearson-Product moment correlation was high (r=0.987), 
indicating that 97.5% of the variance observed in the measure was shared between the 
two devices (Figure 3).  In addition, the intercept of the relationship was not significantly 
different than 0 and the slope of the relationship did not differ from 1.0.  The peak 
oxygen consumption of the subjects did not differ between the two systems 
(ParvoMedics: 4.47 ± 0.73 L/min; PFS: 4.64 ± 0.77 L/min, a 3.8% difference). 
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Figure 2. Comparison of ParvoMedics reference system and PFS measured VO2 at the work-rates 
that all subjects could complete.  * (p<.05 – difference between devices at indicated stage) 
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Figure 3. The relationship between all exercise VO2 measurements collected by the ParvoMedics 
reference system and those made by the PFS. 
  
 
Remaining Metabolic Gas Analysis Measures 
None of the remaining metabolic gas analysis measures examined, i.e., VCO2, VE, FEO2, 
and FECO2, demonstrated any statistically significant differences between the 
ParvoMedics reference system and the PFS within any exercise stage (Figures 4-7). 
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Figure 4. Comparison of ParvoMedics and 
PFS measured VCO2 values. 
Figure 5. Comparison of ParvoMedics and 
PFS measured expired pulmonary ventilation 
values. 
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Figure 6. Comparison of ParvoMedics and 
PFS measured FEO2 values. 
Figure 7. Comparison of ParvoMedics and 
PFS measured FECO2 data. 
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Discussion 
 
Comparison of metabolic gas analysis systems is complicated by human variability in 
day-to-day exercise responses and performance.  One way to control for day-to-day 
variation in exercise responses is to test both systems simultaneously, either in series or 
in parallel.  While this is possible using some systems, the investigators of the current 
study and the designers of the hardware concluded that use of the ParvoMedics system 
and the PFS simultaneously may induce error related to a novel test set up.  For example, 
if the ParvoMedics was sampling “in-line” past the PFS, the increased pressure of gas 
passing through the ParvoMedics may change the mixing bag characteristics of the PFS.  
Thus, two separate tests were performed on the subjects.  While every attempt was made 
to limit variation, including limiting testing for subjects to the same time of day, it has 
been reported that day to day variability in VO2 ranges from 4 to 6% (Shephard, et al, 
1984), while others have reported variability in VO2pk as high as 10 to 12% (Versteeg, et 
al, 1989). 
 
The ParvoMedics reference system and the PFS measures of VO2 did not statistically 
differ for the majority of exercise stages examined (Figure 2).  For the 150 W stage, the 
systems did statistically differ by 5.4%.  This appears to be a random finding that has no 
apparent physiological or methodological explanation.  One of the subjects did 
experience an unusually large difference between the two devices at that stage (2.49 
L/min PFS vs. 2.17 L/min ParvoMedics, a 14.7% difference), and this undoubtedly 
contributed to the statistical difference.  Consideration was given to removing the subject 
as an “outlier” from the data set, but because of the small sample size and the fact that all 
of the other stage data appeared normal for this subject, he was retained in the data set.  
From a clinical relevance stand-point, a 5.4% difference, i.e., the difference between the 
mean values of the two systems at 150 W, is within most of the day-to-day variations of 
VO2 reported in the literature; therefore, based upon the stages of exercise examined, the 
two devices exhibited acceptable agreement.  In addition, the peak VO2 of the subjects 
demonstrated a non-significant difference of 3.8% between the two devices, also within 
the ranges reported in the literature of day-to-day variation in peak VO2. 
 
The VO2 relationship between the two systems shows that the systems exhibit very close 
agreement.  One would expect high agreement between two devices designed to measure 
the same physiological parameter, thus a high Pearson product moment coefficient of 
correlation (r); however, a high r alone does not ensure that the results between the two 
devices are similar (Bland and Altman, 1986).  If a high r is coupled with the slope of the 
relationship being approximately 1.0, and an intercept near 0, the two devices can be 
judged as yielding similar results (Moore, et al, 1997).  In the case of the current 
evaluation, the slope of the relationship between the ParvoMedics and PFS measurements 
of VO2 did not significantly differ from 1.0, nor did the intercept differ from zero. 
 
Interestingly, no differences were seen in expired pulmonary ventilation (VE), even 
though the systems compute pulmonary ventilation using differing methods.  Both the 
PFS and ParvoMedics use a differential pressure pneumotach to measure flow; however, 
the PFS measures flow on the inspiratory side, while the ParvoMedics measures flow on 
the expiratory side.  The software of both systems uses the Haldane Transformation 
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correction (Luft, 1973) to correct for the differences in inspiratory and expiratory 
ventilation when calculating VO2 and VCO2.  The PFS measures inspired ventilation, 
rather than the more traditional expired measurement, to minimize the chance of 
condensation or saliva contamination on the pneumotach surface.  This design feature is 
important for space flight because traditional methods to reduce contamination from 
moisture contained in expired gas rely on gravity and thus would not work in the ISS 
environment. 
 
Use of the PFS during exercise testing on-board ISS should provide improved accuracy 
of the estimates of aerobic fitness which currently rely on the assumption that VO2 per 
given workload is similar on ISS to preflight measurements.  However, the prediction of 
peak oxygen uptake from the heart rate response to submaximal exercise, even with gas 
exchange measurements, will still have limited accuracy.  If accurate aerobic capacity 
measurements are desired by NASA, serious consideration must be given to the 
performance of maximal exercise testing with metabolic gas analysis. 
 
In conclusion, laboratory evaluation of the PFS demonstrated that it provides similar 
results to those measured by the reference metabolic gas analysis system.  It is 
recommended that the PFS be incorporated into the standard periodic fitness evaluation 
testing performed on board ISS. 
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